Research programme: protein tyrosine kinase inhibitor therapeutics - Nexus BioPharma

Drug Profile

Research programme: protein tyrosine kinase inhibitor therapeutics - Nexus BioPharma

Alternative Names: Fyn kinase inhibitor therapeutics - Nexus BioPharma; KV-001; NEX-001; Obesity and diabetes therapeutics - Nexus BioPharma; Weight loss drug - Nexus BioPharma

Latest Information Update: 06 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Nexus BioPharma
  • Developer Albert Einstein College of Medicine; Nexus BioPharma
  • Class Antidementias; Antihyperglycaemics; Antineoplastics; Obesity therapies; Small molecules
  • Mechanism of Action AMP activated protein kinase stimulants; Proto-oncogene protein c-fyn inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Obesity
  • Research Alzheimer's disease; Cancer; Type 2 diabetes mellitus

Most Recent Events

  • 01 Dec 2017 KV 001 licensed to Unknown Company in USA
  • 27 Sep 2016 Preclinical trials in Obesity in USA (unspecified route)
  • 12 Sep 2016 Nexus BioPharma files International patent application for protein tyrosine kinase inhibitors
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top